Niemann-Pick C1 (NPC1), a membrane protein of lysosomes, is required for the export of cholesterol derived from receptor-mediated endocytosis of LDL. Lysosomal cholesterol export is reportedly inhibited by itraconazole, a triazole that is used as an antifungal drug [Xu et al. (2010) Proc Natl Acad Sci USA 107:4764-4769]. Here we show that posaconazole, another triazole, also blocks cholesterol export from lysosomes. We prepared P-X, a photoactivatable cross-linking derivative of posaconazole. P-X cross-linked to NPC1 when added to intact cells. Cross-linking was inhibited by itraconazole but not by ketoconazole, an imidazole that does not block cholesterol export. Cross-linking of P-X was also blocked by U18666A, a compound that has been shown to bind to NPC1 and inhibit cholesterol export. P-X also crosslinked to purified NPC1 that was incorporated into lipid bilayer nanodiscs. In this in vitro system, cross-linking of P-X was inhibited by itraconazole, but not by U18666A. P-X cross-linking was not prevented by deletion of the N-terminal domain of NPC1, which contains the initial binding site for cholesterol. In contrast, P-X cross-linking was reduced when NPC1 contained a point mutation (P691S) in its putative sterolsensing domain. We hypothesize that the sterol-sensing domain has a binding site that can accommodate structurally different ligands.
T he mechanisms by which lipids, such as cholesterol, are transported across membrane bilayers are poorly understood. Recent advances have begun to elucidate one such mechanism, the transport of cholesterol across the lysosome membrane. Mammalian cells supply themselves with cholesterol through the receptormediated endocytosis of cholesterol-carrying LDL (1) . After delivery to lysosomes, the cholesterol is released from LDL and immediately bound by Niemann-Pick C2 (NPC2), a soluble cholesterol carrier. NPC2 delivers cholesterol to Niemann-Pick C1 (NPC1), a complex polytopic membrane protein of 1,278 amino acids embedded in the lysosome membrane (2) . NPC1 transfers its cholesterol to the lysosomal membrane for delivery to other membranes, notably the plasma membrane and the endoplasmic reticulum (3, 4) . Genetic defects in NPC2 or NPC1 cause a fatal disease in which multiple organs fail because of lysosomal cholesterol accumulation (2, 5) .
The mechanism for NPC1 function is beginning to be unraveled through biochemical and structural studies (6) (7) (8) (9) (10) (11) (12) . NPC1 has 13 transmembrane helices and three large domains that project into the lumen (13) . Cholesterol-carrying NPC2 binds to the middle luminal domain (MLD), which positions the protein so that it can transfer its cholesterol to the N-terminal domain (NTD) (11) . This transfer is facilitated by the formation of a channel between NPC2 and the NTD that allows cholesterol to slide from NPC2 to the NTD of NPC1 in a process known as a "hydrophobic handoff" (7) .
A major unsolved problem is how cholesterol moves from the NTD of NPC1 to the membrane. As seen on cryoelectron microscopy and X-ray crystallography, the MLD of NPC1 is an extended structure that is predicted to penetrate through the thick glycocalyx that lines the lysosome membrane (10, 12) . NPC2 binds to the far end of this rod-like structure, which is ∼60 Å from the membrane (11) . The NTD accepts cholesterol at this point, and somehow must traverse the glycocalyx to deliver its cholesterol to the membrane domain of NPC1. This membrane domain contains five transmembrane helices, designated the sterol-sensing domain (SSD) (14) . Within its transmembrane segments, the SSD contains a cleft large enough to accommodate cholesterol, which is postulated to be the site where cholesterol is inserted into the membrane (10) .
Insight into the potential cholesterol-binding site in the NPC1 membrane domain has emerged from studies of U18666A, a derivative of androstenolone that blocks the export of cholesterol from lysosomes (15) . U-X, a photoactivatable derivative of U18666A, was found to cross-link to NPC1 when added to cultured cells (16) . U-X also was found to cross-link to mutant NPC1 containing two substitutions (P202A/F203A) that prevent cholesterol binding to the NTD (7), suggesting that U-X was not binding to the NTD. Instead, U-X cross-linking was abolished by the P691S mutation in the SSD that prevents cholesterol transport. These studies suggest that U18666A inhibits cholesterol transport by binding to the postulated cholesterol-binding site in the SSD (16) .
In the present study, we used a photo-cross-linking approach to define the action of another class of inhibitors of cholesterol export-namely, a series of triazole compounds. Produced by pharmaceutical companies as antifungal drugs (17, 18) , these compounds inhibit a variety of enzymes in sterol biosynthesis, showing higher potency against yeast enzymes vs. mammalian enzymes. It was recently demonstrated that one triazole, itraconazole, inhibits the export of LDL-derived cholesterol from lysosomes of endothelial cells in culture (19) . Here we prepared
Significance
In animal cells, cholesterol is essential for the assembly of membranes and production of steroid hormones and bile acids. Cells obtain cholesterol through receptor-mediated endocytosis of LDL into lysosomes. After lysosomal degradation, LDL-derived cholesterol must cross the lysosomal membrane to execute its functions. Lysosomal export is mediated by Niemann-Pick C1 (NPC1), a membrane protein. Here we show that the triazole drugs posaconazole and itraconazole inhibit lysosomal cholesterol export. A photoactivatable derivative of posaconazole cross-links to NPC1 in intact cells and to purified NPC1 in lipid nanodiscs. A point mutation in the membrane domain of NPC1 prevents lysosomal export of cholesterol and blocks posaconazole cross-linking. a photoactivatable derivative of posaconazole, another triazole, and found that it cross-linked to NPC1 when added to cultured cells. Posaconazole also cross-linked to purified NPC1 that was incorporated into nanodisc lipid bilayers. Cross-linking of posaconazole was inhibited by itraconazole but not by ketoconazole, an imidazole that does not block cholesterol export from lysosomes. These findings indicate that the putative cholesterol-binding site in the SSD of NPC1 may have a relaxed specificity that permits the binding of many seemingly unrelated chemicals, including androstenone derivatives and triazoles.
Results Fig. 1 shows the structures and acid dissociation constants (expressed as pK a values) of the compounds used in this study. Posaconazole and itraconazole are triazoles, and ketoconazole is an imidazole. U18666A and compound A are sterol derivatives. P-X and U-X are derivatives of posaconazole and U18666A, respectively, that were modified by attachment of a benzophenone moiety and an alkyne. The benzophenone allows UV light to induce cross-linking to the backbone atoms of proteins, and the alkyne permits the attachment of azide-containing fluorescent compounds through the use of click chemistry.
The ability of various compounds to block the NPC1-mediated export of cholesterol from lysosomes was tested using a cholesterol re-esterification assay (20) . In this assay, cultured CHO-7 cells are deprived of cholesterol to induce the synthesis of LDL receptors. The cells are then incubated with FCS, which contains LDL. If NPC1 is functional, then LDL-derived cholesterol is exported from the lysosome and re-esterified in the endoplasmic reticulum through the action of acyl-CoA:cholesterol acyltransferase (ACAT). To monitor the re-esterification, we pulse-labeled the cells with [ 14 C]oleate and measured the synthesis of cholesteryl [ 14 C]oleate. To ensure that any inhibition was not caused by diminished uptake and lysosomal degradation of LDL, we routinely monitored the uptake and degradation of 125 I-labeled LDL (20) . No such inhibition was seen in experiments with posaconazole, itrconazole, or U18666A. Fig. 2A shows that posaconazole and P-X are potent inhibitors of cholesterol export from lysosomes, as reflected in the cholesterol re-esterification assay in intact CHO-7 cells, with 50% inhibition occurring at around 7 nM. U18666A and itraconazole were somewhat less potent (50% inhibition at 24 and 34 nM, respectively), whereas ketoconazole and compound A were inactive at concentrations up to 100 nM.
To exclude the possibility that posaconazole and itraconazole were inhibiting ACAT activity directly, we measured the effects of these compounds in an in vitro enzyme assay using a 10 5 g membrane fraction from CHO-7 cells (Fig. 2B) . Neither triazole inhibited ACAT activity, in contrast to the marked inhibitory effect of a known ACAT inhibitor, Sandoz 58-035 (21) . These data suggest that the inhibitory effect of triazoles on cholesterol re-esterification is mediated by inhibition of cholesterol export and not by direct inhibition of ACAT. To measure the cross-linking of P-X and U-X to NPC1, we added the compounds to CHO-7 cells and then exposed the cells to UV light. The cells were disrupted and NPC1 was immunoprecipitated. The immunoprecipitated protein was incubated with Alexa Fluor 532 azide under conditions that catalyzed its attachment to the alkyne on P-X and U-X. After SDS/PAGE, the fluorescent proteins were visualized in situ with a fluorescence detector (Fig.  3A , Upper). The proteins were then transferred to nitrocellulose and incubated with an antibody to NPC1 (Fig. 3A, Lower) . The results indicate that P-X at a concentration of 0.3 μM was crosslinked to bands corresponding to NPC1 (Fig. 3A , Left). Fluorescent labeling was reduced when the cell incubations were conducted in the presence of a 10-fold excess (i.e., 3 μM) of itraconazole, posaconazole, or U18666A, but not with ketoconazole or compound A. A similar pattern of competition was seen when U-X was the cross-linker (Fig. 3A , Right). These results indicate that P-X and U-X bind to NPC1, and that the binding site also recognizes itraconazole and U18666A, but not ketoconazole or compound A. NPC1 appears as a doublet in the SDS/PAGE gels of Fig. 3A . This doublet is due to differential glycosylation, with the upper band reduced to the lower band when the protein is treated with PNGase F (8) . In other experiments when we ran the gels for a shorter time (75 min, compared with 120 min in Fig. 3 ), the two bands were much closer together (Figs. 3B and 4-6).
The experiment shown in Fig. 3A was carried out in parental CHO-7 cells at a P-X concentration of 0.3 μM. To determine the lowest concentration at which P-X cross-linking to NPC1 could be detected, we first produced a stably transfected cell line of CHO-7 cells that overexpress human NPC1. When these TR-4323 cells were incubated with various amounts of P-X, cross-linking to NPC1 was detected at concentrations as low as 10 nM (Fig. 3B) .
To study the binding of the triazoles to purified NPC1, we prepared a cDNA encoding full-length NPC1 with a streptactin tag at the C terminus. The cDNA was inserted into a BacMam vector that was then transduced into human HEK293S GnTI − cells as described previously (10) . Cell membranes were solubilized with n-dodecyl-β-D-maltopyranoside (DDM), and the tagged NPC1 was purified on a column containing Strep-Tactin resin. The purified protein was incorporated into lipid nanodiscs that contained a 9:2 molar ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and cholesterol together with MSP1D1, a membrane scaffold protein, as described in Materials and Methods. Fig. 4A , lane 1, shows that the nanodiscs contained pure NPC1 (Upper) and MSP1D1 (Lower), as determined by SDS/PAGE and Coomassie blue staining. Nanodiscs containing purified NPC1 were incubated with 0.3 μM P-X in the absence or presence of potential competitors. After exposure to UV light and attachment of Alexa Fluor 532, the protein was subjected to SDS/PAGE (Fig. 4B ). In the absence of competitors, P-X was cross-linked to NPC1. Increasing amounts of itraconazole or posaconazole competed for cross-linking, but ketoconazole had much less effect. Quantification of this crosslinking as determined by fluorescence scanning of the bands (22) showed that itraconazole and posaconazole competed with halfmaximal concentrations of ∼1 μM, whereas ketoconazole was more than 10-fold less potent. As shown in Fig. 4B , Bottom, all lanes had similar amounts of NPC1 as determined by immunoblotting.
Our standard procedure for preparing nanodiscs includes 18 mol% cholesterol. To determine whether this cholesterol influences P-X cross-linking, we prepared nanodiscs with no cholesterol and with 46 mol% cholesterol. As shown in Fig. 4C , varying the cholesterol content had no effect on P-X cross-linking.
In previous studies with U-X (16), we showed that cross-linking to NPC1 was not prevented by a point mutation in the NTD that abolishes cholesterol binding (7), indicating that U-X cross-linking is not dependent on the cholesterol-binding site in the NTD. To further test this hypothesis, we prepared a plasmid encoding NPC1 with a deletion of the NTD. The mutant protein, designated NPC1 (ΔNTD), was purified (Fig. 4A, lane 2) and incorporated into nanodiscs in the same fashion as full-length NPC1. Fig. 5 shows that P-X was cross-linked to NPC1(ΔNTD) in the same fashion as full-length NPC1. Moreover, cross-linking was competed by itraconazole and posaconazole, but not by ketoconazole or compound A. Fig. 5 also shows that U18666A did not compete with P-X for cross-linking to NPC1 in nanodiscs. A possible explanation for this unexpected finding (observed in multiple experiments) is provided in Discussion.
In previous studies of intact cells, we observed reduced crosslinking of U-X to the P691S mutant of NPC1 (16) . This mutation occurs in transmembrane helix 5, which is part of the SSD, and it may possibly alter the rigidity of the putative sterol-binding cleft (10) . The mutant protein moves to lysosomes, but it does not transport cholesterol (23, 24) . Moreover, it showed reduced susceptibility to cross-linking when a radiolabeled photoactivated derivative of cholesterol was added to cultured cells (25) . Fig. 6A shows a Coomassie blue-stained SDS/PAGE gel of purified wild type (WT) and mutant NPC1(P691S) proteins incorporated into nanodiscs. Fig. 6B shows reduced cross-linking to the P691S mutant compared with WT in nanodiscs incubated with varying concentrations of P-X. Whereas P-X was cross-linked to WT NPC1 at 0.01 μM, it showed much less cross-linking to the P691S mutant at every concentration tested up to 0.3 μM. We observed that a 6 cells per 150-mm dish in 25 mL of medium A with 5% LPDS as described in Materials and Methods. On day 3, each monolayer received 25 μL of DMSO containing either 0.3 μM P-X or U-X in the presence of 3 μM of one of the following potential competitors: none (N), itraconazole (I), posaconazole (P), ketoconazole (K), U18666A (U), or compound A (A). After incubation for 1 h at 37°C, cells were exposed to UV light and harvested, after which cell lysates were incubated with 1 μg/mL anti-NPC-1 antibody. The solutions were applied to protein A/G agarose beads, washed, and eluted as described in Materials and Methods. (B) Cross-linking at different concentrations of P-X. TR-4323 cells overexpressing NPC1 were set up as above. On day 3, each monolayer received 25 μL of DMSO containing the indicated amount of P-X. After incubation for 1 h at 37°C, cells were exposed to UV light and harvested, after which cell lysates were incubated with 25 μL of anti-FLAG M2 magnetic beads, washed, and eluted as described in Materials and Methods. In A and B, eluted proteins were subjected to fluorescent labeling using click chemistry, followed by 8% SDS/PAGE and in-gel fluorescence scanning (Upper) or immunoblotting with 0.5 μg/mL anti-NPC1 (Lower). Quantification of bands in the upper lanes in A was carried out as described in Materials and Methods. "Relative intensity" values of 1.0 in A refer to samples (lanes 1 and 7) that did not receive competitor compound.
small fraction of the P691S mutant protein migrated near the top of the SDS/PAGE gel, indicating a tendency toward aggregation. To ensure a valid comparison, we equalized the amount of nonaggragated WT and mutant proteins in the nanodiscs, as determined by blotting with anti-NPC1 (Fig. 6B, Bottom) .
Discussion
In this work we have defined properties of the SSD of NPC1, and described approaches to studying this region in the future. We showed that posaconazole and itraconazole, two antifungal triazoles, inhibited cholesterol export from lysosomes of mammalian cells in culture. P-X, a photoactivatable derivative of posaconazole, was cross-linked to NPC1 when exposed to UV light after incubation with cultured cells. In addition, we prepared pure NPC1, incorporated it into lipid bilayer nanodiscs, and showed that P-X could be cross-linked to the pure protein. The specificity of the cross-linking reaction was confirmed by data showing that crosslinking was inhibited competitively by excess posaconazole and itraconazole, but not by ketoconazole, a related compound that contains an imidazole rather than a triazole moiety.
Two lines of evidence suggest that P-X cross-links to the membrane domain of NPC1. First, in the nanodisc assay with purified proteins, P-X cross-linking was not affected by deletion of the NTD, which is the initial cholesterol-binding site in NPC1 (26) . Second, P-X binding was markedly reduced when the purified NPC1 contained the P691S mutation in the membranous SSD. This mutation has been shown to prevent the cross-linking of U-X, a photoactivatable derivative of U18666A that also blocks cholesterol export from lysosomes (16) . Considered together, these data indicate that U18666A, posaconazole, and itraconazole may all bind to a common site that may lie in the SSD. This site is required for the function of NPC1 in transporting LDL-derived cholesterol from lysosomes.
An unexpected finding in the present study was the failure of U18666A to block the cross-linking of P-X to purified NPC1 in nanodiscs (Fig. 6B) . This failure occurred even though U18666A did block cross-linking of P-X to NPC1 when added to intact cells (Fig. 3) . A possible explanation lies in the pK a values shown in Fig. 1. U18666A is a basic compound that may concentrate in the acidic environment of lysosomes. This concentration may enhance the apparent potency of U18666A when added to intact cells. Posaconazole and itraconazole are acidic compounds that should not concentrate in lysosomes (27). U18666A appears to be equally potent to itraconazole in intact cells where U18666A reaches high intralysosomal concentrations, but it would be much less potent when added to nanodiscs in vitro.
Our current findings indicate that the triazoles inhibit lysosomal cholesterol export by binding to the membrane domain of NPC1, but they do not reveal whether these compounds compete for binding to the same site as cholesterol or whether they bind . Nanodiscs with varying amounts of cholesterol were prepared as described in Materials and Methods. After incubation for 1 h at 37°C, each mixture was subjected to UV cross-linking and fluorescent labeling. Proteins were subjected to 8% SDS/PAGE, followed by in-gel fluorescence scanning (Upper) or immunoblotting with 0.5 μg/mL anti-NPC1 (Lower).
to another site that inhibits cholesterol binding allosterically. Arguing against a single binding site is the observation that P-X cross-linking is not inhibited even when the nanodiscs contain 46 mol% of cholesterol (Fig. 4C ). This argument is not conclusive, however. It is possible that posaconazole and cholesterol bind to a common site but the nanodisc cholesterol is not in an orientation that allows access to this site. It is conceivable that cholesterol binding requires delivery by the NTD, which could open a channel in the SSD (11) in much the same way as NPC2 does when it delivers cholesterol to the NTD (7). Somehow, U18666A and the triazoles may gain access to the SSD without requiring opening by the NTD.
The alternative possibility is that the membrane domain of NPC1 contains an allosteric regulatory site to which U18666A and the triazoles bind. If such an allosteric site exists, then its ability to bind must depend on the configuration of proline 691. The P691S mutation in the SSD disrupts cholesterol export (16, 23, 24) , triazole binding (Fig. 6) , and cross-linking of photocholesterol (25) , an observation that suggests a single binding site. A solution to this conundrum may emerge from more detailed structural studies of the binding site(s) for cholesterol, triazoles, and U18666A in the membrane domain of NPC1.
Materials and Methods
Chemical Compounds for Cross-Linking. Itraconazole, ketoconazole, and U18666A were obtained from Sigma-Aldrich, and posaconazole was purchased from eNovation Chemicals. U-X and compound A were synthesized as described previously (16) . P-X was synthesized as described in SI Materials and Methods. All compounds were dissolved in DMSO and stored as 10 mM stock solutions in multiple aliquots at −80°C.
Nanodisc Reconstitution of Purified NPC1. A cDNA encoding full-length human NPC1 (GI: 83305902) with a C-terminal StrepTactin epitope tag (WSHPQFEK) (28) was cloned into pEG BacMam (29) . The baculovirus was transduced into HEK293S GnTI − cells (American Type Culture Collection; CRL-3022). At 50 h postinfection, the cells were disrupted by sonication in buffer containing 20 mM Hepes at pH 7.0, 150 mM NaCl, 1 mM phenylmethyl sulfonyl fluoride, and 5 μg/mL each of leupeptin and aprotinin. After low-speed centrifugation, the resulting supernatant was incubated with 1% (wt/vol) DDM (final concentration) for 2 h at 4°C, after which the mixture was centrifuged again, and the supernatant was loaded onto Strep-Tactin resin (IBA). After two washes with buffer containing 20 mM Hepes at pH 7.0, 150 mM NaCl, and 0.02% DDM, the protein was eluted with the same buffer (but with 5 mM desthiobiotin) and then concentrated to ∼5 mg/mL. For all experiments except those shown in Fig.  4B , purified NPC1 was incorporated into lipid nanodiscs containing 18 mol% cholesterol as described previously (30) .
To form the lipid stock solution, 9 mg of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (Avanti) and 1 mg of cholesterol (Avanti) dissolved in chloroform were dried by argon stream, and residual chloroform was further removed by vacuum desiccation for overnight. Lipids were rehydrated in 0.5 mL of buffer containing 20 mM Hepes pH 7.0, 150 mM NaCl, and 25 mM sodium cholate, and then sonicated in a water bath, resulting in a clear lipid stock solution at 20 mg/mL. Purified NPC1 protein (∼5 mg/mL) in 0.02% DDM was mixed with membrane scaffold protein MSP1D1 (30) and the lipid stock solution at a molar ratio of 1:10:100 and then incubated at 4°C for 1 h. To remove excess detergent, Bio-Beads SM2 (0.7 g per 1 mL mixture; Bio-Rad) were added, followed by incubation at 4°C for 4 h with constant rotation. The Bio-Beads were removed by centrifugation, and the resulting supernatant was applied to a Superdex 200 size-exclusion column (GE Healthcare) in buffer containing 20 mM Hepes pH 7.0 and 150 mM NaCl. The peak corresponding to NPC1 reconstituted in lipid nanodiscs was collected for cross-linking assays.
Two mutant versions of human NPC1, one in which the NTD (amino acids 24-260) was deleted and the other containing an amino acid substitution (P691S) (23, 24) , were expressed, purified, and incorporated into nanodiscs as described above. The resulting proteins are referred to as NPC1(ΔNTD) nanodiscs and NPC1(P691S) nanodiscs.
Immunoprecipitation of Cross-Linked NPC1. For immunoprecipitation of P-X or U-X binding proteins, parental CHO-7 or mutant TR-4323 cells overexpressing NPC1 were set up on day 0 in 25 mL of medium A with 5% lipoproteindeficient serum (LPDS) at a density of 1.6 × 10 6 cells per 150-mm dish. On day 3, each monolayer received a direct addition of DMSO (final concentration, 0.2%) containing the indicated cross-linker and various competitor compounds as described in the figure legends. After incubation for 1 h at 37°C in the dark and without a change of media, the cells were irradiated for 10 min at room temperature under 306-nm UV light (Atlanta Light Bulb Co.) in a UV Stratalinker 2400 apparatus (Stratagene). All subsequent operations Fig. 5 . Cross-linking of P-X to purified NPC1(ΔNTD) reconstituted in nanodiscs. Each reaction contained, in a final volume of 100 μL of buffer A, 0.1 μg of either NPC1 nanodiscs or NPC1(ΔNTD) nanodiscs, 0.3 μM P-X, and 3 μM of one of the following: none (N), itraconazole (I), posaconazole (P), ketoconazole (K), U18666A (U), or compound A (A). After incubation for 1 h at 37°C, the mixtures were subjected to UV cross-linking and fluorescent labeling. Proteins were subjected to 8% SDS/PAGE, followed by in-gel fluorescence scanning (Upper) or immunoblotting with 0.5 μg/mL anti-NPC1 (Lower). Fig. 6 . Cross-linking of P-X to purified NPC1(P691S) in nanodiscs. (A) SDS/PAGE of purified and reconstituted WT NPC1 and mutant NPC1(P691S) used for cross-linking. Proteins were purified and reconstituted as described in Materials and Methods and then subjected to a 4-12% Bis-Tris gradient gel. The amount of protein was normalized so that similar amounts of WT and mutant NPC1 proteins (∼0.3 μg) were loaded onto the gel. The asterisk denotes the position of migration of MSP1D1. The arrow denotes aggregated NPC1(P691S) nanodiscs that did not enter gel. (B) Cross-linking of purified proteins. Each reaction contained, in a final volume of 100 μL of buffer A, 0.1 μg of either NPC1 nanodiscs or NPC1(P691S) nanodiscs, and the indicated amount of P-X. After incubation for 1 h at 37°C, the mixtures were subjected to UV cross-linking and fluorescent labeling. Proteins were subjected to 8% SDS/PAGE, followed by in-gel fluorescence scanning (Upper) or immunoblotting with 0.5 μg/mL anti-NPC1 (Lower).
were carried out at 4°C. Cells were scraped from the dishes, and each cell suspension was subjected to centrifugation at 1 × 10 3 × g for 5 min. The pellet was washed once with PBS and then solubilized with 1 mL of buffer containing 50 mM Tris·HCl pH 7.5, 150 mM NaCl, 1% (wt/vol) DDM, and Protease Inhibitor Mixture. Each solubilized lysate was passed through a 22.5-gauge needle 10 times, rotated for 1 h, and clarified by centrifugation at 1.5 × 10 6 × g for 30 min. The supernatant was then transferred to a fresh tube.
CHO-7 cell lysates were incubated with monoclonal anti-NPC1 as described in the figure legends. After rotating for 1 h, 100 μL of Protein A/G PLUS Agarose Immunoprecipitation Reagent (beads) were added, followed by rotation overnight, and centrifugation at 1 × 10 3 × g for 5 min. The pelleted beads were washed five times with 1 mL of wash buffer (50 mM Tris·HCl 7.5, 150 mM NaCl, and 0.02% DDM), suspended in 1 mL of wash buffer mixed with 1% SDS, and then boiled for 5 min, after which the mixture was clarified by centrifugation for 5 min at 1 × 10 3 × g. TR-4323 cell lysates were incubated with anti-FLAG M2 magnetic beads for 1 h, after which the beads were applied to a magnet, washed three times with 1 mL of wash buffer, and eluted with 100 μL of wash buffer containing 15 μg of 3× FLAG peptide.
The purified proteins from the CHO-7 and TR-4323 lysates were then tagged with Alexa Fluor 532 by means of copper-catalyzed azide-alkyne cycloaddition (click chemistry) (31, 32) . The reactions were carried out by mixing an aliquot of each SDS lysate (43 μL), in a final volume of 50 μL, with 3 μL of 1.7 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), 2 μL of 50 mM CuSO 4 , 1 μL of 50 mM Tris(2-carboxyethyl)phosphine (TCEP), and 1 μL of 1.25 mM Alexa Fluor 532 azide. The mixture was incubated at room temperature for 1 h.
To visualize the fluorescent-labeled proteins by in-gel fluorescence, 20-μL aliquots of each sample were mixed with 5× loading dye and subjected to 8% SDS/PAGE, after which the gels were scanned with a Typhoon image scanner (GE Healthcare; filter setting: excitation, 533 nM; emission, 555 nm; high sensitivity). After scanning, the proteins were transferred to nitrocellulose, blotted with rabbit monoclonal anti-NPC1, and visualized by chemiluminescence using goat anti-rabbit IgG conjugated to horseradish peroxidase, as described below. Quantification of fluorescent-tagged NPC1 bands in SDS/PAGE was carried out using ImageJ (22) .
UV Cross-Linking of P-X to NPC1 in Nanodiscs. Each reaction contained, in a final volume of 100 μL of buffer A (50 mM Hepes pH 7.5 and 150 mM NaCl), 0.1 μg of WT NPC1 or NPC1(ΔNTD) reconstituted in nanodiscs, 0.3 μM P-X, and various amounts of itraconazole, posaconazole, or ketoconazole as indicated in the figure legends. After incubation for 1 h at 37°C, the mixture was subjected to UV cross-linking for 10 min. After the addition of SDS (final concentration 1%), the cross-linked P-X was tagged with Alexa Fluor 532 using click chemistry as described above. An aliquot of each sample was subjected to 8% SDS/PAGE, and fluorescent-labeled proteins were visualized by in-gel fluorescence and quantified by ImageJ as described above. After scanning the gel, the proteins were transferred to nitrocellulose and blotted with rabbit monoclonal anti-NPC1.
Reproducibility. Each experiment was repeated at least three times, with similar results obtained.
Additional information on materials, synthesis of posaconazole P-X crosslinker, cell culture, generation of TR-4323 cells, cholesterol esterification assays, and immunoblot analysis is provided in SI Materials and Methods.
